Andrew Berens
Stock Analyst at Leerink Partners
(2.33)
# 2,561
Out of 5,154 analysts
99
Total ratings
46.99%
Success rate
-2.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $24.08 | +140.86% | 11 | Mar 3, 2026 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $37.08 | -59.55% | 6 | Jun 13, 2022 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $4.45 | +79.78% | 1 | Jan 23, 2026 | |
| GLTO Galecto | Initiates: Outperform | $46 | $28.91 | +59.11% | 1 | Jan 7, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $27.47 | +45.61% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $99.41 | +49.88% | 3 | Nov 17, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.33 | +181.43% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $10.42 | +139.92% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $115.00 | -47.83% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $13.60 | -33.82% | 6 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $6 | $5.51 | +8.89% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $759.86 | +0.28% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.05 | +981.97% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $143.93 | -33.30% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $95.94 | -18.70% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $15.10 | +85.43% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $194.22 | -59.32% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.30 | +1,076.47% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $15.74 | +58.83% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.60 | +614.29% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $3.04 | +2,103.95% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $17.80 | +12.36% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $16.95 | +47.49% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $10.27 | -22.10% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $24.08
Upside: +140.86%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $37.08
Upside: -59.55%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $4.45
Upside: +79.78%
Galecto
Jan 7, 2026
Initiates: Outperform
Price Target: $46
Current: $28.91
Upside: +59.11%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $27.47
Upside: +45.61%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $99.41
Upside: +49.88%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.33
Upside: +181.43%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $10.42
Upside: +139.92%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $115.00
Upside: -47.83%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $13.60
Upside: -33.82%
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.51
Upside: +8.89%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $759.86
Upside: +0.28%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.05
Upside: +981.97%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $143.93
Upside: -33.30%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $95.94
Upside: -18.70%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $15.10
Upside: +85.43%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $194.22
Upside: -59.32%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.30
Upside: +1,076.47%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $15.74
Upside: +58.83%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.60
Upside: +614.29%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $3.04
Upside: +2,103.95%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $17.80
Upside: +12.36%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $16.95
Upside: +47.49%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $10.27
Upside: -22.10%